Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856451 | 0.85 | LTA4H (0.49) | TBXAS1L3MBTL1NFATC1GSK3BDYRK1A | |
| SCHEMBL4855278 | 0.83 | CYP11B1 (0.42) | NFATC1GSK3BDYRK1ACYP19A1 | |
| SCHEMBL4856398 | 0.80 | CYP11B1 (0.53) | NFATC1GSK3BDYRK1ACYP19A1 | |
| SCHEMBL4854988 | 0.79 | CYP1A2 (0.46) | NFATC1GSK3BDYRK1AMAPK1 | |
| SCHEMBL21917167 | 0.77 | DYRK1A (0.67) | NFATC1GSK3BDYRK1A | |
| SCHEMBL32691572 | 0.77 | DYRK1A (0.67) | NFATC1GSK3BDYRK1A | |
| SCHEMBL15374360 | 0.75 | CYP19A1 (0.49) | DYRK1APOLBCYP19A1 | |
| SCHEMBL4851778 | 0.75 | DYRK1A (0.50) | NFATC1GSK3BDYRK1AHRH2 | |
| SCHEMBL4849426 | 0.74 | CYP17A1 (0.38) | NFATC1GSK3BDYRK1A | |
| SCHEMBL4851858 | 0.73 | CYP19A1 (0.56) | GSK3BDYRK1ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | TBXAS1 518/4885L3MBTL1 3156/4885NFATC1 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.